<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>CHAMP - Le Fonti New Pharma Italy</title>
	<atom:link href="https://www.newpharmaitaly.it/tag/champ/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.newpharmaitaly.it/tag/champ/</link>
	<description>Il portale delle news in ambito farmaceutico</description>
	<lastBuildDate>Mon, 24 Sep 2018 14:50:11 +0000</lastBuildDate>
	<language>it-IT</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://www.newpharmaitaly.it/wp-content/uploads/2022/12/cropped-favicon-new-pharma-italy-32x32.jpg</url>
	<title>CHAMP - Le Fonti New Pharma Italy</title>
	<link>https://www.newpharmaitaly.it/tag/champ/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Ipsen riceve parere positivo del CHAMP per Cabozantinib</title>
		<link>https://www.newpharmaitaly.it/parere-positivo-del-champ-per-cabozantinib/</link>
		
		<dc:creator><![CDATA[Elvis Kondi]]></dc:creator>
		<pubDate>Mon, 24 Sep 2018 14:50:11 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<category><![CDATA[ADR]]></category>
		<category><![CDATA[Alexandre Lebeaut]]></category>
		<category><![CDATA[cabozantinib]]></category>
		<category><![CDATA[CELESTIAL]]></category>
		<category><![CDATA[CHAMP]]></category>
		<category><![CDATA[Ema]]></category>
		<category><![CDATA[HCC]]></category>
		<category><![CDATA[Humanitas Cancer Center]]></category>
		<category><![CDATA[IPN]]></category>
		<category><![CDATA[ipsen]]></category>
		<category><![CDATA[IPSEY]]></category>
		<category><![CDATA[Lorenza Rimassa]]></category>
		<guid isPermaLink="false">http://www.newpharmaitaly.it/?p=3146</guid>

					<description><![CDATA[<p>Giudizio favorevole per il trattamento di seconda linea dei pazienti con carcinoma epatocellulare (HCC) Ipsen (Euronext: IPN; ADR: IPSEY) ha annunciato oggi che il Comitato per i medicinali per uso umano (CHMP), il comitato scientifico dell&#8217;Agenzia europea per i medicinali (EMA), ha espresso parere positivo per cabozantinib come monoterapia per il trattamento del carcinoma epatocellulare [&#8230;]</p>
<p>L'articolo <a href="https://www.newpharmaitaly.it/parere-positivo-del-champ-per-cabozantinib/">Ipsen riceve parere positivo del CHAMP per Cabozantinib</a> proviene da <a href="https://www.newpharmaitaly.it">Le Fonti New Pharma Italy</a>.</p>
]]></description>
		
		
		
			</item>
	</channel>
</rss>
